Mid-stage CNS biotech Al­to Neu­ro­science plots $89M IPO

Al­to Neu­ro­science joined Fractyl Health in out­lin­ing its IPO price range on Mon­day morn­ing as the two biotechs look to build on the mo­men­tum gen­er­at­ed by CG On­col­o­gy and Ar­riVent Bio­phar­ma last week.

The mid-stage CNS biotech plans to raise about $89 mil­lion in IPO pro­ceeds if it prices at the mid­point of its pro­posed $14 to $16 range. Al­to ex­pects to sell 6.7 mil­lion shares $AN­RO in its de­but on the NYSE, like­ly lat­er this week. Most biotech star­tups list on the Nas­daq, but the NYSE has been at­tempt­ing to grow its life sci­ences ros­ter in re­cent years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER